Viela Bio (VIE) Prices 3.6M Share Common Offering at $47/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Viela Bio (VIE) Announces Proposed 3M Share Public Offering of Common Stock
May 26, 2020 7:24 AM EDTViela Bio, Inc. (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock from the selling stockholders.
Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Guggenheim Securities are acting as the joint... More
